France · Delayed Price · Currency is EUR TME Pharma Company Description
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma.
It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatment of diabetic nephropathy.
The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022.
TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
| Country | Netherlands |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Diede van den Ouden |
Contact Details
Address: Max-Dohrn-Strasse 8-10 Berlin, 10589 Germany | |
| Phone | 49 30 16637082 0 |
| Website | tmepharma.com |
Stock Details
| Ticker Symbol | ALTME |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | NL0012044762 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Diede M. van den Ouden | Chief Executive Officer and Director |
| Dr. Jarl Ulf Jungnelius M.D., Ph.D. | Chief Medical Officer |